Adjunct Professor Bruno Meloni has been a key figure in stroke research at the Perron Institute for over 25 years. Before joining the institute, Professor Meloni’s research focused on the application of in vitro cultivation and molecular techniques to characterize medically important protozoan parasites, earning him a PhD from Murdoch University in 1993. Since joining the Perron Institute in 1996, he was instrumental in establishing the Stroke Research group’s laboratory and has played a major role in shaping its direction. His research focuses on understanding the mechanisms involved in ischaemic brain injury, identifying potential neuroprotective targets, and developing new therapies.

Professor Meloni’s research is focused on understanding the mechanisms involved in ischaemic brain injury, the identification of potential neuroprotective targets and the development of new therapies. Recently, the research has identified a novel class of neuroprotective peptides known as cationic arginine-rich peptides (CARPs), which are being developed into neurotherapeutics to reduce brain injury after stroke, and other acute and chronic neurological disorders. Professor Meloni is the Chief Scientific Officer for the ASX listed company Argenica Therapeutics, which was established as a spin-out from UWA and Perron Institute to progress the clinical development of a lead neuroprotective peptide (ARG-007) as a stroke therapeutic.

View Publications    Email

 

Find out more about Professor Meloni: